Cocrystal Pharma, Inc. (COCP) 

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Show less

Over the last 12 months, insiders at Cocrystal Pharma, Inc. have bought $0 and sold $0 worth of Cocrystal Pharma, Inc. stock.

On average, over the past 5 years, insiders at Cocrystal Pharma, Inc. have bought $686,719 and sold $1.7M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,015,229 shares for transaction amount of $2M was made by FROST PHILLIP MD ET AL () on 2023‑04‑04.